ALLO today
$0.90-$0.03 (-3.41%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourLeaning Bullish
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns up above $1.37
Key levels
Resistance$1.16
Resistance$1.04
Support$0.86
Latest news & SEC filings
ProductAllogene Therapeutics Shares Early Data From Phase 1 Study of ALLO-329
EarningsAllogene Therapeutics holds Q3 2026 earnings call
All ALLO news →About Allogene Therapeutics
Allogene Therapeutics develops donor-derived, gene-edited T cell therapies designed to be stored and given to patients without a patient-specific manufacturing step. Its main programs target large B-cell lymphoma, kidney cancer, and autoimmune disorders including lupus. The company handles its own cell production at a facility in California and holds rights to its products in the United States, Europe, and the United Kingdom.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Allogene Therapeutics, Inc. (ALLO)
What Is the Price Target for ALLO?
SEPT Low Target
$3.85
SEPT Mid Target
$8.00
SEPT High Target
$10.00
Analyst Consensus
$8.00
Is ALLO a Buy or Sell Right Now?
Thesis
- •Revenue growing -76.8% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALLO.
Start Free Trial →Is ALLO Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$6.87
25
Moat Score
NONE
2/9
Piotroski Score
-6.5
Altman Z-Score
What Is Smart Money Doing with ALLO?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Parker Geoffrey M. | officer | Sale | 36,342 | $49K | Oct 21, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ALLO Growth Story
Revenue YoY
-76.8%
3yr Revenue CAGR
-94.2%
EPS Growth YoY
34.09%
FCF Growth YoY
25.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for ALLO
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ALLO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 10:43:27 | $0.88 | 5,481 | $$5K | SELL |
| 24:27:45 | $0.91 | 5,000 | $$5K | SELL |
| 24:27:18 | $0.91 | 4,898 | $$4K | SELL |
| 22:58:58 | $0.91 | 4,353 | $$4K | SELL |
| 22:57:10 | $0.91 | 5,000 | $$5K | SELL |
5 dark pool trades shown · $$22K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ALLO
PREVIEWSEPT Investing provides real-time options flow tracking for ALLO, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $0.5 | Nov 20 | 9 | $$49 | 1 | SWEEP |
| CALL | $1.5 | May 21 | 191 | $$40 | 2 | SWEEP |
| CALL | $1.5 | Feb 19 | 100 | $$25 | 5 | SWEEP |
| CALL | $1.5 | Feb 19 | 100 | $$500 | 100 | BLOCK |
| CALL | $1.5 | Feb 19 | 100 | $$375 | 75 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Allogene Therapeutics, Inc. (ALLO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ALLO — frequently asked questions
What is ALLO stock price today?
Allogene Therapeutics, Inc. (ALLO) is at $0.90, down 3.41% (-$0.03) at the Nov 11, 2026 close.
Why is ALLO stock moving today?
Latest ALLO news — Nov 9, 2026: Allogene Therapeutics Shares Early Data From Phase 1 Study of ALLO-329 · Nov 5, 2026: Allogene Therapeutics holds Q3 2026 earnings call
What is the ALLO price target?
The average analyst price target for ALLO is $8.00, ranging from $4 to $10, based on 5 analysts. Latest: Jefferies maintains on Apr 15, 2026.
What do analysts rate ALLO?
Analyst ratings for ALLO: 0 Buy, 8 Hold, 0 Sell — consensus Hold.
Did ALLO beat earnings?
ALLO last reported on Nov 5, 2026: EPS -$0.15 vs -$0.15 expected — a miss of 2.3%.
Does ALLO pay a dividend?
ALLO does not currently pay a dividend.
What are ALLO support and resistance levels?
Support: $0.86. Resistance: $1.04, $1.16, $1.27.
What are insiders doing with ALLO?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on ALLO?
Nov 9, 2026: Allogene Therapeutics Shares Early Data From Phase 1 Study of ALLO-329 · Nov 5, 2026: Allogene Therapeutics holds Q3 2026 earnings call